Please download the program file here: 
| # | Time-Location | Session | Title | Presenter | |
|---|---|---|---|---|---|
| 1 | 14:30 - 14:45 HALL II NIKOLAI N. ANICHKOV |
Effect of AGTR1 A1166C gene variant on lesion of coronary artery and mortality in patients with acute myocardial infarction. | Dr. Trần Công Duy | ||
| 2 | 14:45 - 15:00 HALL II NIKOLAI N. ANICHKOV |
Applying artificial intelligence in predicting coronary artery disease in patients with heart valve disease undergoing heart valve surgery | Dr. Nguyễn Minh Kha | ||
| 3 | 15:00 - 15:15 HALL II NIKOLAI N. ANICHKOV |
Changes in aortic elasticity index using M-mode echocardiography in patients with type 2 diabetes in Vietnam. | Dr. Lương Việt Thắng | ||
| 4 | 15:15 - 15:30 HALL II NIKOLAI N. ANICHKOV |
Association between metabolic syndrome and short-term outcomes in patients with acute myocardial infarction | Dr. Nguyễn Nhật Tài | ||
| 5 | 15:30 - 15:45 HALL II NIKOLAI N. ANICHKOV |
The Correlation between Liver Fibrosis and the 10-Year Estimated Risk of Cardiovascular Disease in Adults with Metabolic-Associated Fatty Liver Disease: A Cross-Sectional Study in Vietnam. | Dr. Đặng Nguyễn Ngọc Hải | ||
| 6 | 15:45 - 16:00 HALL II NIKOLAI N. ANICHKOV |
Relationship of left atrial strain with SCORE 2 and SCORE 2-OP scores to assess cardiovascular risk | Dr. Lê Thị Ngọc Hân | ||
| 7 | 16:00 - 16:15 HALL II NIKOLAI N. ANICHKOV |
Treatment rate achieving LDL-C target in patients who received coronary artery stents at Bach Mai hospital | Dr. Nguyễn Thị Quỳnh Trang | ||
| 8 | 16:15 - 16:30 HALL II NIKOLAI N. ANICHKOV |
Evaluation of SCORE2, SCORE2-OP SCORE and dyslipidemia in hypertension patients | Dr. Nguyễn Vĩnh Phúc | ||
| 9 | 16:30 - 16:45 HALL II NIKOLAI N. ANICHKOV |
Association Between ASCVD Risk Score and Left Ventricular Function in Individuals with Normal Coronary Arteries: A Retrospective CT Study. | Trần Công Trình | ||
| 10 | 16:45 - 17:00 HALL II NIKOLAI N. ANICHKOV |
Relationship between lipoprotein(a) concentration and coronary artery disease on MSCT. | Dr. Lê Thị Lan Hương | ||
| 11 | 17:30 - 17:40 HALL II NIKOLAI N. ANICHKOV |
Assoc.Prof. Phạm Nguyễn Vinh | |||
| 12 | 17:40 – 18:05 HALL II NIKOLAI N. ANICHKOV |
Strategies for managing LDL-C in clinical practice | Prof. Peter J.Lansberg | ||
| 13 | 18:05 - 18:30 HALL II NIKOLAI N. ANICHKOV |
Early protective benefits of high-intensity statins | Dr. Lương Cao Sơn | ||
| 14 | 18:30 - 18:50 HALL II NIKOLAI N. ANICHKOV |
||||
| 15 | 18:50 - 19:00 HALL II NIKOLAI N. ANICHKOV |
Assoc.Prof. Phạm Nguyễn Vinh | |||
| 16 | 08:30 - 08:45 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Family medicine approach in atherosclerosis disease prevention | Assoc.Prof. Hồ Thị Kim Thanh | |
| 17 | 08:45 - 09:00 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Primary prevention of cardiovascular disease due to atherosclerosis: role of polygen risk scoring system in clinical practice | Dr. Nguyễn Văn Sĩ | |
| 18 | 09:00 - 09:15 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Multimodality imaging for the Assessment of UNstable Plaques. | Assoc.Prof. Nguyễn Thị Thu Hoài | |
| 19 | 09:15- 09:30 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Subclinical atherosclerosis: to what extent have we paid attention? | Nguyễn Hữu Đức | |
| 20 | 09:30 - 09:45 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | How to prevent and treat coronary atherosclerosis in the elderly? | Assoc.Prof. Nguyễn Văn Trí | |
| 21 | 9:45 - 10:00 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Application of artificial intelligence in the context of prevention and treatment of atherosclerosis. | Assoc.Prof. Lê Minh Khôi | |
| 22 | 10:00 - 10:15 HALL I ARIKA ENDO |
PRECISION MEDICINE IN RISK EVALUATION OF ATHEROSCLEROSIS | Discussion and conclusion | CTĐ + BCV | |
| 23 | 10:15 - 10:30 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Akira Endo: the great biologist - the father of the first statin, a wonderful inspiration | Dr. Nguyễn Văn Sĩ | |
| 24 | 10:30 - 10:45 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Value of lipoproten in clinical implication | Dr. Hoàng Thị Yến | |
| 25 | 10:45 - 11:00 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Evaluation of small dense LDL concentration with enzymatic colorimetric methods in acute coronary syndrome patients at Cho Ray Hospital " | Dr. Trần Thành Vinh | |
| 26 | 11:00 - 11:15 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | APO-B: from theory to reality and hope for atherosclerosis risk management in the future | Dr. VŨ HOÀNG VŨ | |
| 27 | 11:15- 11:30 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Lp(a) : Past, Present, and Future | Prof. Trương Quang Bình | |
| 28 | 11:30 - 11:45 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Risk of cardiovascular disease due to atherosclerosis: diagnostic and prosnotic role of hs-cTnT | Assoc.Prof. Hồ Huỳnh Quang Trí | |
| 29 | 11:45 - 12:00 HALL I ARIKA ENDO |
BIOCHEMISTRY & IMMUNOLOGY IN ATHEROSCLEROSIS DIAGNOSIS AND TREATMENT" | Discussion and conclusion | CTĐ + BCV | |
| 30 | 12:00 - 12:15 HALL I ARIKA ENDO |
INFLAMMATION AND IMMUNOLOGY IN ATHEROSCLEROSIS" | Inflammation and immunology tests in atherosclerosis: what should we do? | Dr. Nguyễn Minh Hà | |
| 31 | 12:15- 12:30 HALL I ARIKA ENDO |
INFLAMMATION AND IMMUNOLOGY IN ATHEROSCLEROSIS" | Important role of inflammation factor in residual cardiovascular risk | Assoc.Prof. Hồ Thượng Dũng | |
| 32 | 12:30- 12:45 HALL I ARIKA ENDO |
INFLAMMATION AND IMMUNOLOGY IN ATHEROSCLEROSIS" | Role of inflammatory factors in reducing atherosclerosis burden: time to care | Assoc.Prof. Phạm Nguyễn Vinh | |
| 33 | 12:45 - 13:00 HALL I ARIKA ENDO |
INFLAMMATION AND IMMUNOLOGY IN ATHEROSCLEROSIS" | Inflammation in cardiovascular diseases: important points for cardiologist | Nguyễn Thanh Hiền | |
| 34 | 13:00 - 13:15 HALL I ARIKA ENDO |
INFLAMMATION AND IMMUNOLOGY IN ATHEROSCLEROSIS" | Discussion and conclusion | CTĐ + BCV | |
| 35 | 13:15 - 13:30 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Case report: normal LDL-C concentration in a case of severe atherosclerois despite intensive treatment | Dr. Nguyễn Thị Mai Ngọc | |
| 36 | 13:30- 13:45 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Hyperlipoprotein(a): the defiant genetic factors | Assoc.Prof. Trương Thanh Hương | |
| 37 | 13:45 - 14:00 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Lp(a) in atherosclerotic cardiovascular disease: Data from Vietnam | Dr. Kim Ngọc Thanh | |
| 38 | 14:00 - 14:15 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Evaluation of lipoprotein (a) in medical check-up workers at Thong Nhat Hospital | Dr. Ngô Kiến Đức | |
| 39 | 14:15 - 14:30 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Hemodialysis in treatment of hyperlipoprotein(a) and other dyslipidemia entities in Vietnam: where are we? | Dr. Trần Minh Giang | |
| 40 | 14:30 - 14:45 HALL I ARIKA ENDO |
LP(A) IN CLINICAL PRACTICE: WHERE ARE WE? | Discussion and conclusion | CTĐ + BCV | |
| 41 | 14:45 - 15:00 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Physical training and atherosclerosis prevention | Lê Hữu Đồng | |
| 42 | 15:00 - 15:15 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Vegetarian diet in Asian population and atherosclerosis | Dr. Ngô Minh Hùng | |
| 43 | 15:15 - 15:30 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Overweight and obese cardiovasculor patients: how to combine nutrition and weight loss treatment appropriately | Nguyễn Viết Quỳnh Thư | |
| 44 | 15:30 - 15:45 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | What can we do in case of cardiovascular patients with smoking addiction? | Dr. Lê Khắc Bảo | |
| 45 | 15:45- 16:00 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Paradox in choosing anti-P2Y12i medication in acute coronary syndrome patients with smoking | Dr. Trần Hòa | |
| 46 | 16:00 - 16:15 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Current status of weight loss treatment and its benefits in obese patients with cardiovascular disease. | Dr. Nguyễn Quang Thảo | |
| 47 | 16:15 - 16:30 HALL I ARIKA ENDO |
LIFESTYLE MODIFICATION STRATEGIES IN ATHEROSCLEROSIS PREVENTION | Discussion and conclusion | CTĐ + BCV | |
| 48 | 16:30 - 16:45 HALL I ARIKA ENDO |
VERY HIGH RISK ATHEROSCLEROSIS PREVENTION: SHOULD WE START WITH HIGH DOSE STATIN OR COMBINATION STRATEGY? | Lipid control in patients at high cardiovascular risk: risk management or numbers management? | Dr. Lê Hoàng Bảo | |
| 49 | 16:45 - 17:00 HALL I ARIKA ENDO |
VERY HIGH RISK ATHEROSCLEROSIS PREVENTION: SHOULD WE START WITH HIGH DOSE STATIN OR COMBINATION STRATEGY? | High-intensity statins: my first choice for prevention in patients at high cardiovascular risk. | Dr. Nguyễn Quốc Thái | |
| 50 | 17:00 - 17:15 HALL I ARIKA ENDO |
VERY HIGH RISK ATHEROSCLEROSIS PREVENTION: SHOULD WE START WITH HIGH DOSE STATIN OR COMBINATION STRATEGY? | Blood cholesterol optimal control in primary and secondary prevetion: I will combine Atorvastatin and Ezetimibe. | Đỗ Xuân Chiến | |
| 51 | 17:15 - 17:30 HALL I ARIKA ENDO |
VERY HIGH RISK ATHEROSCLEROSIS PREVENTION: SHOULD WE START WITH HIGH DOSE STATIN OR COMBINATION STRATEGY? | Discussion and conclusion | CTĐ + BCV | |
| 52 | 08:30 - 08:45 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Vietnam dyslipidemias management guidelines 2024: main points | Prof. Huỳnh Văn Minh | |
| 53 | 08:45 - 09:00 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Guidelines for management of dyslipidemia and prevention for ASCVD in Japan | Prof. Mariko Shiba | |
| 54 | 09:00 - 09:15 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Korean Guidelines for the Management of Dyslipidemia | Prof. Jaetaek Kim | |
| 55 | 09:15 - 09:30 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Lifestyle changes, diet, and physical activity for cardiovascular prevention, focus on Asian populations | Prof. Ta Chen Su | |
| 56 | 09:30 - 09:45 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Atherosclerosis in children and young people: why should we care? | Prof. Borge Nordestgaard | |
| 57 | 09:45 - 10:00 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | New dyslipidemias management strategies | Prof. Dirk Blom | |
| 58 | 10:00 - 10:15 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | How to better implement the guidelines for lipid management ? | Prof. Peter J.Lansberg | |
| 59 | 10:15 - 10:30 HALL II NIKOLAI N. ANICHKOV |
CONTEMPORARY GUIDELINES IN DYSLIPIDEMIA MANAGEMENT AND HOW TO BETTER IMPLEMENT THE GUIDELINES IN THE CLINICAL PRACTICE | Discussion and conclusion | CTĐ + BCV | |
| 60 | 10:30 - 10:45 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | Environmental Pollution and Cardiovascular Health. | Prof. Ta Chen Su | |
| 61 | 10:45 - 11:00 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | Management of obesity to prevent atherosclerosis | ||
| 62 | 11:00 - 11:15 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | New trends in the treatment and prevention of cardiovascular disease - 2024 | Prof. Đặng Vạn Phước | |
| 63 | 11:15 - 11:30 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | Lp(a): new cardiovascular risk factor that needs to be paid attention | Prof. Borge Nordestgaard | |
| 64 | 11:30 - 11:45 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | Residual cardiovascular risk management: challenges and solutions | Dr. Trương Phi Hùng | |
| 65 | 11:45 - 12:00 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | NON-HDL in atherosclerosis disease: where are we? | Assoc.Prof. Trương Thanh Hương | |
| 66 | 12:00 - 12:15 HALL II NIKOLAI N. ANICHKOV |
NEW CARDIOVASCULAR RISK FACTORS AND PRIMARY PREVENTION OF ATHEROSCLEROSIS DISEASE | Discussion and conclusion | CTĐ + BCV | |
| 67 | 12:15 - 12:30 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | Report of new variant in FH with new generation of genomic sequencing | Assoc.Prof. Hoàng Văn Sỹ | |
| 68 | 12:30- 12:45 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | Severe hypertriglyceridemia with diabetes: two cases of young women with gene mutation | Chu Lý Hải Vân | |
| 69 | 12:45 - 13:00 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | Diffuse Coronary Artery Lesions in a Female Patient with Early Myocardial Infarction and FH: A Case Report. | Lý Quang Sang | |
| 70 | 13:00 - 13:15 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | FH management in Vietnam | Dr. Kim Ngọc Thanh | |
| 71 | 13:15 - 13:30 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | FH, HoFH: experiences from Japan | Prof. Mariko Shiba | |
| 72 | 13:30 - 13:45 HALL II NIKOLAI N. ANICHKOV |
FAMILIAL HYPERCHOLESTEROLEMIA (FH): REALITY IN VIETNAM AND WORLD EXPERIENCES | Discussion and conclusion | CTĐ + BCV | |
| 73 | 13:45 - 14:00 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | From cholesterol to statins: a century journey | Nguyễn Dương Khang | |
| 74 | 14:00 - 14:15 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | Do we need the new strategies to manage LDL-C? An update for practicing clinicians. | Prof. Peter J.Lansberg | |
| 75 | 14:15 - 14:30 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | New Trends in Personalization and Precision Medicine: Application in the Treatment of Lipid Disorders | Prof. Đặng Vạn Phước | |
| 76 | 14:30 - 14:45 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | Fibrate: Finished or Still Fighting? | Assoc.Prof. Trần Văn Huy | |
| 77 | 14:45 - 15:00 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | 2024: the year of new solutions in lipoprotein-lowering treatment | Prof. Trương Quang Bình | |
| 78 | 15:00 - 15:15 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | Apheresis lipid: history - now and the future | Prof. Dirk Blom | |
| 79 | 15:30 - 15:45 HALL II NIKOLAI N. ANICHKOV |
CHOLESTEROL CENTURY AND DYSLIPIDEMIAS MANAGEMENT STRATEGIES: STATINS OR NON-STATINS | Discussion and conclusion | CTĐ + BCV | |
| 80 | 15:45 - 16:00 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Early combination of LDL-C lowering drugs: who and when? | Assoc.Prof. Hoàng Văn Sỹ | |
| 81 | 16:15 -16:30 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Dyslipidemias management in very high risk patients in Vietnam: current problems and future solutions? | Dr. Vũ Quỳnh Nga | |
| 82 | 16:00 - 16:15 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Dyslipidemias management update: combination therapy to reach treament goal | Assoc.Prof. Phạm Nguyễn Vinh | |
| 83 | 16:30 - 16:45 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Very high risk atherosclerosis patient with statin allergy: a case report | Lê Đình Phương | |
| 84 | 16:45 - 17:00 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Statin intolerance: what to do? | Assoc.Prof. Trần Văn Huy | |
| 85 | 17:00 - 17:15 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Statin-associated rhabdomyolysis: A case report" | Dr. Trần Đức Trung | |
| 86 | 17:15 - 17:30 HALL II NIKOLAI N. ANICHKOV |
DIFFICULT SITUATIONS WHEN TREATING WITH STATINS: POOR RESPONSE - NOT REACHING THE TARGET, INTOLERANCE, ALLERGIES, ... WHAT WILL WE DO? | Discussion and conclusion | CTĐ + BCV | |
| 87 | 08:30 - 08:45 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Individualized treatment of diabtes patients according to ABCDE criteria | Assoc.Prof. Trần Quang Nam | |
| 88 | 08:45 - 09:00 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Atherosclerosis prediction value of polygen risk score in type 2 diabetes patients | Dr. Lê Hoàng Bảo | |
| 89 | 09:05 - 09:15 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Prognosis improvement in diabetes patients with high risk of cardiovascular disease due to atherosclerosis | Dr. Trần Quang Khánh | |
| 90 | 09:15 - 09:30 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Metabolic dysfunction in diabetes patients: role of SGLT2i in cardiovascular incident prevention | Dr. Lê Thanh Liêm | |
| 91 | 09:30 - 09:45 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Challenges and solutions in obesity treatment: an endocrinologist expert´s view | Dr. Trần Quang Khánh | |
| 92 | 09:45 - 10:00 HALL III JELIX JACOB MARCHAND |
MANAGEMENT OF DIABETES PATIENT WITH ATHEROSCLEROSIS | Discussion and conclusion | CTĐ + BCV | |
| 93 | 10:00 - 10:05 HALL III JELIX JACOB MARCHAND |
SATELLITE OF NOVARTIS - ATHEROSCLEROSIS AND HEART FAILURE IN CLINICAL REALITY | Introduction | Prof. Huỳnh Văn Minh | |
| 94 | 10:05 - 10:25 HALL III JELIX JACOB MARCHAND |
SATELLITE OF NOVARTIS - ATHEROSCLEROSIS AND HEART FAILURE IN CLINICAL REALITY | Stable heart failure patients: are they being forgotten? | Lê Hoài Nam | |
| 95 | 10:25 - 10:45 HALL III JELIX JACOB MARCHAND |
SATELLITE OF NOVARTIS - ATHEROSCLEROSIS AND HEART FAILURE IN CLINICAL REALITY | Treatment optimization in heart failure patients with coronary artery disease: role of ARNI | Dr. Bùi Long | |
| 96 | 10:45 - 11:00 HALL III JELIX JACOB MARCHAND |
SATELLITE OF NOVARTIS - ATHEROSCLEROSIS AND HEART FAILURE IN CLINICAL REALITY | Discussion and conclusion | CTĐ + BCV | |
| 97 | 11:00 - 11:15 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | The role of Aspirin in primary prevention of atherosclerotic cardiovascular diseases: who needs priority? | Nguyễn Thanh Hiền | |
| 98 | 11:15 - 11:30 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Atherosclerosis and cancer | Assoc.Prof. Nguyễn Thị Thu Hoài | |
| 99 | 11:30 - 11:45 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Role of traditional medicine in atherosclerosis | Assoc.Prof. Nguyễn Thị Bay | |
| 100 | 11:45 - 12:00 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Respiratory disturbances related to sleep: recognition and first response | Dr. Lê Khắc Bảo | |
| 101 | 12:00 - 12:15 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Valvular heart disease and atherosclerosis | Assoc.Prof. Lê Minh Khôi | |
| 102 | 12:15 - 12:30 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Statin therapy in elderly patients after myocardial infarction: what is different and what should be considered? | Dr. Nguyễn Thành Sang | |
| 103 | 12:30 - 12:45 HALL III JELIX JACOB MARCHAND |
ATHEROSCLEROSIS IN CHRONIC DISEASES" | Discussion and conclusion | CTĐ + BCV | |
| 104 | 12:45 - 13:00 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Role of SGLT2i in atherosclerosis patients with chronic kidney disease: latest guidelines | Prof. Trương Quang Bình | |
| 105 | 13:00 - 13:15 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Heart failure treatment in coronary artery disease patient | Assoc.Prof. Phạm Nguyễn Vinh | |
| 106 | 13:15 - 13:30 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Early approach - Reduce renal-cardio incidents in heart failure patients with atherosclerosis | Dr. Trịnh Việt Hà | |
| 107 | 13:30 - 13:45 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Heart failure after myocardial infarction prevention: what is new in 2024? | Prof. Trương Quang Bình | |
| 108 | 13:45 - 14:00 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Dr. Viêm Hoàng Long | ||
| 109 | 14:00 - 14:15 HALL III JELIX JACOB MARCHAND |
NEW TREND IN RENAL AND HEART FAILURE PROTECTION RELATED TO ATHEROSCLEROSIS | Discussion and conclusion | CTĐ + BCV | |
| 110 | 14:15 - 14:30 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | MASH Current definition of MASLD/MASH | Dr. Võ Huy Văn | |
| 111 | 14:30 - 14:45 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | MASH diagnosis approach | Assoc.Prof. Bùi Hữu Hoàng | |
| 112 | 14:45 - 15:00 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | Role of ultrasound in MASLD/MASH diagnosis | Nguyễn Quang Trọng | |
| 113 | 15:00 - 15:15 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | 2024 updates on MASH management | Assoc.Prof. Võ Duy Thông | |
| 114 | 15:15 - 15:30 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | Obesity and cardiovascular disease - what is the relationship? | Assoc.Prof. Đỗ Quang Huân | |
| 115 | 15:30 - 15:45 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | Lipid-lowering therapy for the management of non-alcoholic fatty liver disease (NAFLD) | Prof. Brian Tomlinson | |
| 116 | 15:45 - 16:00 HALL III JELIX JACOB MARCHAND |
METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS [MASLD/MASH] AND OBESE RELATED TO ATHEROSCLEROSIS | Discussion and conclusion | CTĐ + BCV | |
| 117 | 16:30 - 16:45 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | Polypills in optimal management of hypertension - dyslipidemias in ASCVD patients | Dr. Nguyễn Mạnh Quân | |
| 118 | 16:15 - 16:30 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | Optimal hypertension management in hypertensive patients with co-morbidities | A.Prof. Hoàng Anh Tiến | |
| 119 | 16:00 - 16:15 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | Early approach - long-term prognosis improvement for hypertensive patients with atherosclerosis | Dr. Nguyễn Thị Mai Ngọc | |
| 120 | 16:45 - 17:00 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | Efficacy of febuxostat compared to allopurinol in hyperuricemia in hypertensive patients | Dr. Ngô Hoàng Toàn | |
| 121 | 17:00 - 17:15 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | New medication combination to reduce risk in hypertensive patients with coronary artery disease | Dr. Trần Hòa | |
| 122 | 17:15 - 17:30 HALL III JELIX JACOB MARCHAND |
INTENSIVE MANAGEMENT OF HYPERTENSIVE PATIENTS IN ATHEROSCLEROSIS PREVENTION | Discussion and conclusion | CTĐ + BCV | |
| 123 | 08:30 - 08:45 HALL IV HAI THUONG LAN ONG |
ROLE OF NON-INVASIVE IMAGING IN ATHEROSCLEROSIS DIAGNOSIS | Subclinical atherosclerosis: diagnosis and prevention | Assoc.Prof. Trần Viết An | |
| 124 | 08:45 - 09:00 HALL IV HAI THUONG LAN ONG |
ROLE OF NON-INVASIVE IMAGING IN ATHEROSCLEROSIS DIAGNOSIS | Role of vascular ultrasound in diagnosis of subclinical to high-risk atherosclerosis | Nguyễn Quang Trọng | |
| 125 | 09:00 - 09:15 HALL IV HAI THUONG LAN ONG |
ROLE OF NON-INVASIVE IMAGING IN ATHEROSCLEROSIS DIAGNOSIS | Role of CT-scan in diagnosis and risk stratification in coronary atherosclerosis | Nguyễn Đức Chỉnh | |
| 126 | 09:30 - 09:45 HALL IV HAI THUONG LAN ONG |
ROLE OF NON-INVASIVE IMAGING IN ATHEROSCLEROSIS DIAGNOSIS | Unstable plaque: recognition and management | Assoc.Prof. Huỳnh Văn Thưởng | |
| 127 | 09:45 - 10:00 HALL IV HAI THUONG LAN ONG |
ROLE OF NON-INVASIVE IMAGING IN ATHEROSCLEROSIS DIAGNOSIS | Discussion and conclusion | CTĐ + BCV | |
| 128 | 10:00 - 10:15 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Acute coronary syndrome update in the view of unstable plaque imaging. | Assoc.Prof. Hồ Thượng Dũng | |
| 129 | 10:15 - 10:30 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Patients with high-risk and fragile atherosclerotic plaques: we should treat conservatively. | Assoc.Prof. Hoàng Văn Sỹ | |
| 130 | 10:30 - 10:45 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Patients with high-risk and fragile atherosclerotic plaques: I will place a stent. | Dr. Hoàng Văn | |
| 131 | 10:45 - 11:00 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Antiplatelet de-escalation approach in ASCVD patients | Assoc.Prof. Nguyễn Văn Tân | |
| 132 | 11:00 - 11:15 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Where are we in post-acute coronary syndrome management? | Dr. Ngô Minh Hùng | |
| 133 | 11:15- 11:30 HALL IV HAI THUONG LAN ONG |
UNSTABLE AND HIGH RISK PLAQUE: NEW TRENDS IN DIAGNOSIS CRITERIA AND TREATMENT | Discussion and conclusion | CTĐ + BCV | |
| 134 | 11:30 - 11:45 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Recognition and management of thrombus plaque (atherothrombosis) in cath lab | Assoc.Prof. Nguyễn Ngọc Quang | |
| 135 | 11:45 - 12:00 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | A case report of massive thrombus-induced acute myocardial infarction: what is the rational management? | Dr. Lê Văn Tuyến | |
| 136 | 12:00 - 12:15 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Individualized antiplatelet treatment in acute coronary syndrome due to thrombus atherosclerosis and ACSelerate application | Dr. Lương Cao Sơn | |
| 137 | 12:15 - 12:30 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Paradox in thrombus atherosclerosis treatment in Vietnam: reality and solutions | Dr. Lê Cao Phương Duy | |
| 138 | 12:30 - 12:45 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Patients protection after myocardial infarction: should not stop in the cath lab | Dr. Vũ Quỳnh Nga | |
| 139 | 12:45 - 13:00 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Optimizing treatment of dyslipidemia in cardiovascular disease prevention: current situation and prospects | Lê Đình Phương | |
| 140 | 13:00 - 13:15 HALL IV HAI THUONG LAN ONG |
ATHEROTHROMBOSIS AND ACUTE CORONARY SYNDROME: RECOGNITION AND MANAGEMENT | Discussion and conclusion | CTĐ + BCV | |
| 141 | 13:15 - 13:30 HALL IV HAI THUONG LAN ONG |
ATHEROSCLEROSIS MANAGEMENT AND STROKE PREVENTION | Statin and stroke patients: benefits and recommendations | Assoc.Prof. Nguyễn Huy Thắng | |
| 142 | 13:30 - 13:45 HALL IV HAI THUONG LAN ONG |
ATHEROSCLEROSIS MANAGEMENT AND STROKE PREVENTION | Ischemia stroke prevention and LDL-C: the lower, the better? | Nguyễn Đức Chỉnh | |
| 143 | 13:45: 14:00 HALL IV HAI THUONG LAN ONG |
ATHEROSCLEROSIS MANAGEMENT AND STROKE PREVENTION | Diagnosis and treatment update: extracranial carotid artery stenosis due to atherosclerosis | Dr. Tôn Thất Trí Dũng | |
| 144 | 14:00 - 14:15 HALL IV HAI THUONG LAN ONG |
ATHEROSCLEROSIS MANAGEMENT AND STROKE PREVENTION | Atrial fibrillation, stroke and atherosclerosis: relationship and management | A.Prof. Hoàng Anh Tiến | |
| 145 | 14:15- 14:30 HALL IV HAI THUONG LAN ONG |
ATHEROSCLEROSIS MANAGEMENT AND STROKE PREVENTION | Discussion and conclusion | CTĐ + BCV | |
| 146 | 14:30 - 14:45 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Antiplatelet management data on Asian patients and its implication in Vietnam | Dr. VŨ HOÀNG VŨ | |
| 147 | 14:45 - 15:00 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Reality and challenges in LDL-C management after coronary stenting | Dr. Hoàng Văn | |
| 148 | 15: 00 - 15:15 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | New journey on atherosclerosis treatment: mangament of small vessel and complex lesion with drug-eluting balloon | Trần Trà Giang | |
| 149 | 15:15 - 15:30 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Correlation between coronary stent advancement and atherosclerotic lesions complexity: reporting the 2 years outcomes of Bioadaptor RCT | Assoc.Prof. Nguyễn Văn Tân | |
| 150 | 15:30 - 15:45 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Practical experience using drug-coated balloons in intervention of peripheral atherosclerotic lesions. | Dr. Võ Tuấn Anh | |
| 151 | 15:45 - 16:00 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Large multifocal aneurysms threatening rupture of the abdominal and thoracic aorta: the most appropriate approach to diagnosis and treatment in patients with very high cardiovascular risk." | Lâm Đắc Huy | |
| 152 | 16:00 - 16:10 HALL IV HAI THUONG LAN ONG |
ADVANCEMENTS IN ATHEROSCLEROSIS MANAGEMENT | Discussion and conclusion | CTĐ + BCV | |
| 153 | 16:10 - 16:15 HALL IV HAI THUONG LAN ONG |
SATELLITE OF NOVO-NORDISK :: Individualized treament in obesity patients with clinical cardiovascular disease | Introduction | ||
| 154 | 16:15- 16:35 HALL IV HAI THUONG LAN ONG |
SATELLITE OF NOVO-NORDISK :: Individualized treament in obesity patients with clinical cardiovascular disease | Role of GLP-1 RA in weight reduction and cardiovascular safety profile | Assoc.Prof. Nguyễn Thị Thu Hoài | |
| 155 | 16:35 - 16:50 HALL IV HAI THUONG LAN ONG |
SATELLITE OF NOVO-NORDISK :: Individualized treament in obesity patients with clinical cardiovascular disease | Individualized treament in obesity patients with clinical cardiovascular disease | Mã Tùng Phát | |
| 156 | 16:50 - 18:00 HALL IV HAI THUONG LAN ONG |
SATELLITE OF NOVO-NORDISK :: Individualized treament in obesity patients with clinical cardiovascular disease | Discussion and conclusion | CTĐ + BCV |
The 2nd Vietnam Atherosclerosis Society Scientific Conference
